Thalidomide-d4

Thalidomide-d4 is a deuterium labeled Thalidomide. Thalidomide inhibits cereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, with a Kd of ~250 nM, and has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties[1][2].

Product Specifications

CAS Number

[1219177-18-0]

UNSPSC

12352005

Hazard Statement

H301, H360

Target

Apoptosis; Autophagy; Ligands for E3 Ligase; Molecular Glues

Type

Isotope-Labeled Compounds

Related Pathways

Apoptosis; Autophagy; PROTAC

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Purity

98.71

Solubility

10 mM in DMSO|DMF : ≥ 12mg/mL|DMSO : ≥ 12mg/mL

Smiles

O=C1N(C(CC2)C(NC2=O)=O)C(C3=C1C([2H])=C([2H])C([2H])=C3[2H])=O

Molecular Formula

C13H6D4N2O4

Molecular Weight

262.26

Precautions

H301, H360

References & Citations

[1]Fischer ES, et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature. 2014 Aug 7;512 (7512) :49-53.|[2]Sun X, et al. Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling. Med Sci Monit. 2018 May 15;24:3193-3203.